> Details

Zee, Sze-Tsing; Kwok, Lam-Fung; Kee, Ka-Man; Fung, Ling-Hiu; Luk, Wing-Pan; Chan, Tsun-Leung; Leung, Chin-Pang; Yu, Pik-Wa; Hung, Jhan; SzeTo, Kit-Ying; Chan, Wai-Leng; Tang, Siu-Fai; Lin, Wai-Chi; Ma, Shiu-Kwan; Lee, Koon-Hung; Lau, Chor-Chiu; Yung, Wai-Hung

Impact of COVID-19 Vaccination on Healthcare Worker Infection Rate and Outcome during SARS-CoV-2 Omicron Variant Outbreak in Hong Kong

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Impact of COVID-19 Vaccination on Healthcare Worker Infection Rate and Outcome during SARS-CoV-2 Omicron Variant Outbreak in Hong Kong
  • Contributor: Zee, Sze-Tsing; Kwok, Lam-Fung; Kee, Ka-Man; Fung, Ling-Hiu; Luk, Wing-Pan; Chan, Tsun-Leung; Leung, Chin-Pang; Yu, Pik-Wa; Hung, Jhan; SzeTo, Kit-Ying; Chan, Wai-Leng; Tang, Siu-Fai; Lin, Wai-Chi; Ma, Shiu-Kwan; Lee, Koon-Hung; Lau, Chor-Chiu; Yung, Wai-Hung
  • imprint: MDPI AG, 2022
  • Published in: Vaccines
  • Language: English
  • DOI: 10.3390/vaccines10081322
  • ISSN: 2076-393X
  • Keywords: Pharmacology (medical) ; Infectious Diseases ; Drug Discovery ; Pharmacology ; Immunology
  • Origination:
  • Footnote:
  • Description: <jats:p>Immune escape is observed with SARS-CoV-2 Omicron (Pango lineage B.1.1.529), the predominant circulating strain worldwide. A booster dose was shown to restore immunity against Omicron infection; however, real-world data comparing mRNA (BNT162b2; Comirnaty) and inactivated vaccines’ (CoronaVac; Sinovac) homologous and heterologous boosting are lacking. A retrospective study was performed to compare the rate and outcome of COVID-19 in healthcare workers (HCWs) with various vaccination regimes during a territory-wide Omicron BA.2.2 outbreak in Hong Kong. During the study period from 1 February to 31 March 2022, 3167 HCWs were recruited, and 871 HCWs reported 746 and 183 episodes of significant household and non-household close contact. A total of 737 HCWs acquired COVID-19, all cases of which were all clinically mild. Time-dependent Cox regression showed that, compared with two-dose vaccination, three-dose vaccination reduced infection risk by 31.7% and 89.3% in household contact and non-household close contact, respectively. Using two-dose BNT162b2 as reference, two-dose CoronaVac recipient had significantly higher risk of being infected (HR 1.69 p &lt; 0.0001). Three-dose BNT162b2 (HR 0.4778 p&lt; 0.0001) and two-dose CoronaVac + BNT162b2 booster (HR 0.4862 p = 0.0157) were associated with a lower risk of infection. Three-dose CoronaVac and two-dose BNT162b2 + CoronaVac booster were not significantly different from two-dose BNT162b2. The mean time to achieve negative RT-PCR or E gene cycle threshold 31 or above was not affected by age, number of vaccine doses taken, vaccine type, and timing of the last dose. In summary, we have demonstrated a lower risk of breakthrough SARS-CoV-2 infection in HCWs given BNT162b2 as a booster after two doses of BNT162b2 or CoronaVac.</jats:p>
  • Access State: Open Access